Enabling a New Level of Ion Mobility Intelligence

    IonDX provides next-generation ion mobility technology to analyze biologic drugs from glycoproteins and CRISPR-Cas to mRNA and lipid nanoparticles

    New CEO named,Ion Mobility,Soft landing,Cryo-EM sample prep,Latest news
    Monterey, CA, Dec 18, 2023 - IonDX, a life sciences instrumentation company, is pleased to...
    TECHNOLOGY FEATURE 16 October 2023 Soft-landing methods aim to simplify structural biology  ...
  • IMgenius

    Accelerating the next generation of biologic drugs

    broken image


    Applies to a wide range of biologics

    Soft ionization conditions allow native conformations of biomacromolecules to be studied, e.g., non-covalent protein complexes, high molecular weight aggregates, mRNA, glycoproteins, CRISPR-Cas, virus particles, lipid nanoparticles

    broken image


    Fits easily into your lab

    IonDX’s patented ion mobility technology provides powerful analytical characterization in a very compact benchtop design.

    broken image

    Ion Mobility

    Operates at atmospheric pressure

    IMgenius determines the mobility of a population of molecular ions as they travel through a gas under the influence of an electric field. Small ions have higher mobility than larger ions because they experience less drag as they travel through a gas.

  • Enabling a New Level of Ion Mobility Intelligence


    IonDXInc., based in Monterey, CA is commercializing an advanced system to analyze biologic drugs. The current biotherapeutic development cost is extremely high, >$2.5B and 8-10 years to introduce one of these drugs into the market. Our technology aims to improve analytical quality and reduce this cost by implementing a highly informative, fast, and reproducible assay. Our patented ion mobility spectrometers can simultaneously measure five important attributes of protein-based drugs: drug concentration, purity, stability and structural conformation of these molecules. We produce quantitative and correlative measurement in <5 minutes with our bench-top instrument. The short time range is rapid enough to introduce it in bioprocess environment where other technologies are too slow and unreliable. IonDX’s technology, being amenable to other analytical interfaces and automation, can fit into typical biotherapeutic high-throughput workflows, providing unique capability to reduce time and effort to bring a biotherapeutic to market.



    NSF’s SBIR Phase II awarded to IonDX on Sept 10, 2019 in support of ongoing development of our ion mobility spectrometer for macromolecular analysis.



    NSF SBIR Phase I awarded to IonDX for our next-generation stand-alone electrospray ion mobility spectrometer.

  • broken image

    IonDX IMgenius Tech Note

    Check out our Tech Note on the IMgenius instrument

  • broken image

    IonDX Library

    Access scientfic posters describing IonDX technology

    Your Electrospray Ion Mobility Experts

    Decades of experience including development of a medical diagnostic test based on Electrospray Ion Mobility. We are ready for your analytical challenge.



    Higher Order Structure Analysis

    IonDx provides analytical instrumentation and services for electrospray ion mobility of singly charged protein ions. You get non-distorted higher order structure characterization of your proteins, nanoparticles, or even exosomes.

    Expand Your Totality of Evidence

    IonDX's biomolecule comparability studies give you the biophysical fingerprint you need for your biotherapeutic drug